Propanc’s PRP Shows 85% Tumor Inhibition, Preps 2026 Phase 1b Trials
Propanc’s PRP proenzyme therapy achieved over 85% tumor growth inhibition in preclinical pancreatic cancer models and lowered fibrosis and resistance markers in the tumor microenvironment. The company plans Phase 1b trials in 2026 supported by a newly commissioned $100 million facility.
1. Preclinical Efficacy
Propanc’s lead candidate, PRP, inhibited tumor growth by more than 85% in preclinical pancreatic cancer models. Studies also showed reductions in fibrosis and resistance markers while sensitizing tumors to standard chemotherapies and targeting cancer stem cells to lower recurrence risk.
2. Clinical Development Plans
The company has scheduled Phase 1b first-in-human trials for PRP in 2026, initially focusing on pancreatic and ovarian cancers. These trials will evaluate safety, tolerability and preliminary efficacy, particularly chemotherapy sensitization effects in resistant tumor types.
3. Market Opportunity
Propanc aims to capture a segment of the over $3 billion pancreatic cancer treatment market, which has a five-year survival rate of only 13%. By addressing root-cause mechanisms and chemo resistance, PRP could disrupt current standard-of-care regimens if clinical results translate.
4. Manufacturing Investment
A recently commissioned $100 million manufacturing facility supports large-scale production of PRP for clinical studies. This infrastructure positions the company to advance multiple solid tumor programs and streamline the transition from preclinical to clinical stages.